Hi there! For the coming weeks, our blog will be dedicated to our Young SIOP Award winners!
Please meet Holly Pacenta, YI from the United States, in her own words.
I am a junior faculty at Cook Children’s Medical Center in Fort Worth, TX where my primary research and clinical interests are in targeted therapies for relapsed leukemia. I completed my fellowship at Children’s Hospital Colorado in Aurora, CO where I worked on a lab-based project with the goal of identifying new therapeutic targets for individuals with Down syndrome and ALL.
I have continued to build on the foundation that I gained during my fellowship as a junior faculty. While at UT Southwestern Medical Center in Dallas, TX, I was a member of the experimental therapeutics team and gained valuable experience treating patients with Kymriah, the first FDA approved CAR (chimeric antigen receptor) T-cell for pediatric B-ALL.
In my current position at Cook Children’s I am the medical director of the Cellular Immunotherapy Program. On a national level, I am the vice-Principal Investigator for Cook Children’s in the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, and I am also a member of the study committee of the phase I/II TACL study which is evaluating ixazomib in combination with chemotherapy in patients with relapsed or refractory ALL.
I also participate in the Pediatric Real World CAR Consortium (PRWCC) which is evaluating outcomes of patients treated with Kymriah following FDA approval. Through the PRWCC I am leading a project evaluating the outcomes of individuals with Down syndrome and B-ALL treated with Kymriah in a real world setting.
Comments
Post a Comment